The UK’s National Medicines Verification Organisation (NMVO) has been formally established under the name SecurMed UK. The organisation brings together all the main trade bodies from across the medicines supply chain. The five sectors represented are:
- Research-based manufacturers – Association of the British Pharmaceutical Industry (ABPI)
- Generic manufacturers – British Generic Manufacturers Association (BGMA)
- Parallel distributors – British Association of European Parallel Distributors (BAEPD)
- Pharmaceutical wholesalers – Healthcare Distribution Association (HDA)
- Dispensing entities (pharmacies) – Company Chemists Association/National Pharmacy Association (CCA/NPA)
Each sector has one voting director on the board of SecurMed UK, with the pharmacy directorship being held for alternating six month periods by CCA and NPA.
SecurMed’s main purpose will be to establish and maintain a National Medicines Verification System for the UK, as required under the EU Delegated Regulation (2016/161), implementing what is commonly known as the Falsified Medicines Directive (FMD). SecurMed will do this by appointing one of three Blueprint Service Provider (BSP) companies: Aegate, Arvato or Solidsoft Reply. The BSP will develop the UK NMVS and connect all of the UK’s community and hospital pharmacies, dispensing doctors, wholesalers and others who commonly handle and dispense medicines, as well as connecting to the central European Medicines Verification System (EMVS).
The BSP appointment will be handled through a competitive tendering process and is expected to be concluded by the end of 2016, allowing the NMVS to be set up during 2017.